Last update 03 Oct 2024

Edaravone/(+)-2-Decanol

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Compound edaravone, Edaravone and Dexborneol, Edaravone combination
+ [11]
Target-
Mechanism
Neuroprotectants
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
CN (29 Jul 2020),
RegulationBreakthrough Therapy (US), Special Review Project (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC10H22O
InChIKeyACUZDYFTRHEKOS-JTQLQIEISA-N
CAS Registry33758-16-6
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Stroke
CN
29 Jul 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Ischemic StrokeNDA/BLA
CN
29 Jun 2023
Acute Ischemic StrokeNDA/BLA
CN
29 Jun 2023
Cognitive DysfunctionPhase 2
CN
03 Apr 2024
Cerebral HemorrhagePhase 2-01 Mar 2021
Brain InfarctionPhase 1
CN
22 May 2019
Brain InfarctionPhase 1
CN
22 May 2019
Intracranial HemorrhagesPhase 1
US
25 Oct 2018
Amyotrophic Lateral SclerosisIND Application
US
-
Cognition DisordersIND Application
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
914
imzwthpaoz(kwtmpdmhdu) = hesachkzqu kqvdtnnxyh (bsueipfqzg )
Positive
19 Feb 2024
Placebo
imzwthpaoz(kwtmpdmhdu) = tptyutirwh kqvdtnnxyh (bsueipfqzg )
Phase 3
-
hclmxenups(dwtrufbhpz) = 初步分析显示,相对于安慰剂, 先必新舌下片显著改善AIS患者治疗后神经功能恢复及独立生活能力,达到预期疗效终点 pmwiytgszv (ehhssjanmr )
Met
Positive
01 Dec 2022
Placebo
NEWS
ManualManual
Not Applicable
94
fqtxjznxzk(yukyqdqnfl) = peiufnctfx wdxecadqnd (whcmyqmiez, 4.11)
Positive
06 May 2022
fqtxjznxzk(yukyqdqnfl) = qbeyupewam wdxecadqnd (whcmyqmiez, 2.15)
Phase 3
1,165
Edaravone+Dexborneol
iasxzvhnsb(opnfzsgoen) = xfyeddmfcn rzrnczahgg (hlkmlfmshv )
Superior
01 Mar 2021
Edaravone
iasxzvhnsb(opnfzsgoen) = nuukeksghe rzrnczahgg (hlkmlfmshv )
Phase 2
385
wiknsklgxw(yqixxfrvlz): P-Value = 0.6799
Positive
22 Apr 2019
Edaravone
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free